Jivi (Antihemophilic Factor [Recombinant] Pegylated-Aucl) for Hemophilia

Overview
Jivi is a recombinant antihemophilic factor approved by the U.S. Food and Drug Administration (FDA) for the treatment and management of hemophilia A (congenital factor VIII [8] deficiency) in previously treated adults and adolescents aged 12 years and older. It is used for on-demand treatment of bleeding episodes, management of bleeding related to surgey, and routine prophylaxis to reduce the frequency of bleeding episodes. Jivi is not indicated for children under 12 years old, previously untreated patients (PUPs), or for the treatment of von Willebrand disease. Jivi is also known by its drug name, antihemophilic factor (recombinant), PEGylated-aucl.

Jivi belongs to the drug category known as clotting factors. It works by temporarily raising the levels of factor VIII in the blood, allowing the blood to clot more effectively and thus preventing or controlling bleeding episodes in individuals with hemophilia A.

How do I take it?
Prescribing information states that Jivi is administered as an intravenous (IV) infusion after reconstitution from a lyophilized powder. The dosage depends on the purpose of the treatment. For the control of bleeding episodes and perioperative management, the dosage is calculated based on the individual's weight and the desired increase in factor VIII levels. For routine prophylaxis, the initial recommended regimen is administered twice weekly. Based on bleeding episodes, the regimen may be adjusted to every five days or modified to more or less frequent dosing. Jivi should be administered exactly as prescribed by a health care provider.

Side effects
The FDA-approved label for Jivi lists common side effects including headache, cough, nausea, and fever.

Rare but serious side effects may include hypersensitivity reactions (severe allergic reactions), development of factor VIII neutralizing antibodies (which can reduce the effectiveness of the treatment), and immune responses to polyethylene glycol (PEG), particularly in younger children, leading to hypersensitivity symptoms and potential loss of drug effectiveness.

For more information about this treatment, visit:

Label: Jivi (Antihemophilic Factor — Recombinant Pegylated-Aucl Kit — DailyMed

Jivi (Recombinant) — Drugs.com